ArticleESMO open2025
Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe.
Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Next-Generation Sequencing Refines Diagnosis and Expands Precision Medicine Opportunities in Soft Tissue Sarcomas.International journal of molecular sciences · 2026Article
- Exploring Dystrophin Expression and Mutations in theInternational journal of molecular sciences · 2026Article
- Clinicopathological features and departmental distribution of sarcoma patients: a single-center retrospective study.BMC cancer · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcomas comprise a heterogeneous group of malignant tumors of mesenchymal origin where diagnosis plays a crucial role in tailoring disease management and treatment. In this context, there is a lack of data assessing the potential benefit of next-generation sequencing (NGS) reflecting real-world scenarios across different countries. The aim of our analysis includes both the diagnostic refinement and the therapeutic guidance with the use of NGS in sarcoma treatment strategy. MATERIALS AND
methodsWe retrospectively analyzed 694 samples from six sarcoma-expert institutions from three countries in Europe: Greece, Poland, and Spain, thus reflecting a variety of scenarios.
resultsWe identified 90 different sarcoma histological subtypes, of which the most common were leiomyosarcomas (10.1%), Ewing sarcomas (7.5%), and undifferentiated pleomorphic sarcomas (7.3%). In 62 patients (8.9%), using NGS fusion panels specific for diagnosis resulted in a change in the diagnosis. From a therapeutic perspective, NGS panels used for this purpose were suitable to identify single-nucleotide variants and copy number alterations. The most common alterations were mutations that mostly occurred in TP53, followed by RB1, PIK3CA, CDKN2A, CTNNB1, IDH1, NF1, CHECK2, PTEN, BRCA1, and BRCA2. One hundred and thirty-five alterations (19.5%) were actionable according to OncoKB, while four additional alterations (0.6%) were actionable in disagreement with OncoKB.
conclusionsIn conclusion, our data support the clinical utility of NGS fusion panels in diagnosing sarcomas in specific contexts. The therapeutic value of NGS remains limited, as reported before. However, given the overall paucity of molecular data for most sarcoma subtypes, we emphasize the importance of an international effort to collect molecular profiling of sarcomas to guide the design of clinical trials for specific targetable alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.